Céline Colacios
- Centre de Recherches en Cancérologie de Toulouse (CRCT)
Publications
Publications
Targeting ceramide metabolism in melanoma to improve the efficacy of immune checkpoint inhibitor therapy: from basic mechanisms to the clinic.XV SPHINGOLIPID CLUB MEETING, Sep 2024, Erlangen-Nürnberg, Germany |
|
Triple combination of anti-CTLA-4, anti-PD-1 and anti-TNF in mouse melanoma models and advanced melanoma patients.EACR conferences “Defence is the Best Attack: Immuno-Oncology Breakthroughs”, Joan Seoane, May 2023, Barcelona, Spain |
|
Sphingolipid metabolism in cancer immune surveillanceThe Lysophospholipid and Related Mediators Conference: From Bench to Clinic, FASEB, Jul 2021, Distanciel, France |
|
Combining TNF inhibitors to anti-PD-1 and anti-CTLA-4 for the treatment of advanced melanoma patients17ème journées du Cancéropôle Grand Sud-Ouest, Nov 2021, Carcassone, France |
|
Neutral sphingomyelinase 2 heightens anti-melanoma immune response and synergizes with anti-PD-1.Toulouse Oncoweek, Feb 2020, Toulouse, France |
|
Resistance of Melanoma to Immune Checkpoint Inhibitors is Overcome by Targeting the Sphingosine Kinase 1Canceropole GSO, Canceropole GSO, Nov 2019, Arcachon, France |
|
Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy in advanced melanoma patients.FEBS 2019 Sphingolipid Biology: Sphingolipids in Physiology and Pathology, Giovanni D'Angelo, Christopher J. Clarke, Liana C. Silva, May 2019, Cascais, Portugal |
|
Combining TNF-targeting antibodies to immune checkpoint inhibitors in melanomaToulouse Oncoweek, Feb 2018, Toulouse, France |
Use of sk1 as biomarker for predicting response to immune checkpoint inhibitors.France, Patent n° : WO2019162325A1. 2019 |
|
Methods for predicting the survival of patients suffering from melanoma.France, Patent n° : WO2020193746A1. 2019 |
Rôle du TNF et du métabolisme des sphingolipides dans l’immunoéchappement des cancers et l’immunothérapieImmunologie. Université Paul Sabatier (Toulouse 3), 2022 |